Ricks认为礼来的 incretin 领先地位将长期影响全球健康,且四分之三管线在肥胖之外,将带来多元持久增长。
鉴于我们 incretin 管线的深度,我们预计在心血管代谢领域的领先地位和广泛的下一代肥胖药物管线将在未来几十年对全球健康产生重大影响。我们四分之三的临床管线聚焦肥胖以外的疾病,有望带来多元且持久的增长。原文 (en)
Given the depth of our incretin pipeline, we expect our leadership position in cardiometabolic health and broad pipeline of next generation obesity medicines to have a major impact on global health For decades to come. And with 3-fourths of our clinical pipeline focused on diseases outside of obesity, we are developing new medicines. That have the potential to impact a broad range of diseases, and deliver diversified, durable growth, for Lilly and our shareholders.